Literature DB >> 19896697

Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer.

Matthias Choschzick1, Annette Lebeau, Andreas H Marx, Lars Tharun, Luigi Terracciano, Uwe Heilenkötter, Fritz Jaenicke, Carsten Bokemeyer, Ronald Simon, Guido Sauter, Jörg Schwarz.   

Abstract

Cell division cycle 7 is a widely expressed protein kinase implicated in cell division, cell cycle checkpoint mechanisms, and cancer progression. To determine the relationship of cell division cycle 7 protein expression with tumor phenotype, molecular features and prognosis, 2197 highly characterized breast carcinomas were analyzed on a tissue microarray. Detectable cell division cycle 7 expression was found in 1088 (57%) of breast cancer specimens and 228 (11.9%) exhibited a moderate or strong expression. High levels of cell division cycle 7 expression were significantly related to medullary histotype (P < .0001); high tumor grade (P < .0001); negative estrogen receptor status (P < .0001); high Ki67 expression level (P < .0001); p53 and p16 overexpression (P < .0001); and amplification of HER2 (P < .0001), c-myc (P < .0001), MDM2 (P = .043), CCND1 (P = .0084), and ESR1 (P = .0012) as well as with the number of amplified genes (P < .0001). There was also a tendency towards worse prognosis in cell division cycle 7 positive as compared to negative breast cancers. The relationship between cell division cycle 7 and number of amplifications was independent from tumor proliferation raising the possibility of a direct influence of cell division cycle 7 expression for amplification development. In conclusion, cell division cycle 7 is a replication associated protein with relationships to gene amplification and genomic instability in breast carcinomas. These data support the potential utility of newly developed small molecule cell division cycle 7 inhibitors as a therapeutic alternative in at least a subset of breast carcinomas. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896697     DOI: 10.1016/j.humpath.2009.08.008

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

1.  PIWI-interacting RNA 021285 is involved in breast tumorigenesis possibly by remodeling the cancer epigenome.

Authors:  Alan Fu; Daniel I Jacobs; Aaron E Hoffman; Tongzhang Zheng; Yong Zhu
Journal:  Carcinogenesis       Date:  2015-07-25       Impact factor: 4.944

2.  Subcellular proteomics reveals a role for nucleo-cytoplasmic trafficking at the DNA replication origin activation checkpoint.

Authors:  Claire M Mulvey; Slavica Tudzarova; Mark Crawford; Gareth H Williams; Kai Stoeber; Jasminka Godovac-Zimmermann
Journal:  J Proteome Res       Date:  2013-02-06       Impact factor: 4.466

3.  Serum Proteomic Signatures of Male Breast Cancer.

Authors:  Eleni Zografos; Athanasios K Anagnostopoulos; Aggeliki Papadopoulou; Evangelia Legaki; Flora Zagouri; Evangelos Marinos; George T Tsangaris; Maria Gazouli
Journal:  Cancer Genomics Proteomics       Date:  2019 Mar-Apr       Impact factor: 4.069

4.  Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.

Authors:  Mary Jo Fackler; Christopher B Umbricht; Danielle Williams; Pedram Argani; Leigh-Ann Cruz; Vanessa F Merino; Wei Wen Teo; Zhe Zhang; Peng Huang; Kala Visvananthan; Jeffrey Marks; Stephen Ethier; Joe W Gray; Antonio C Wolff; Leslie M Cope; Saraswati Sukumar
Journal:  Cancer Res       Date:  2011-08-08       Impact factor: 12.701

5.  Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer.

Authors:  Nathaniel Melling; Johanna Muth; Ronald Simon; Carsten Bokemeyer; Luigi Terracciano; Guido Sauter; Jakob Robert Izbicki; Andreas Holger Marx
Journal:  Diagn Pathol       Date:  2015-07-25       Impact factor: 2.644

6.  The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds.

Authors:  Nanda Kumar Sasi; Kanchan Tiwari; Fen-Fen Soon; Dorine Bonte; Tong Wang; Karsten Melcher; H Eric Xu; Michael Weinreich
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

7.  Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness.

Authors:  Zubeyde Erbayraktar; Begum Alural; Resat Serhat Erbayraktar; Erdogan Pekcan Erkan
Journal:  Cancer Cell Int       Date:  2016-11-18       Impact factor: 5.722

8.  A Dual Inhibitor of Cdc7/Cdk9 Potently Suppresses T Cell Activation.

Authors:  Elijah W Chen; Neil Q Tay; Joanna Brzostek; Nicholas R J Gascoigne; Vasily Rybakin
Journal:  Front Immunol       Date:  2019-07-25       Impact factor: 7.561

9.  High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer.

Authors:  Patrick Lebok; Melike Öztürk; Uwe Heilenkötter; Fritz Jaenicke; Volkmar Müller; Peter Paluchowski; Stefan Geist; Christian Wilke; Eicke Burandt; Annette Lebeau; Waldemar Wilczak; Till Krech; Ronald Simon; Guido Sauter; Alexander Quaas
Journal:  Oncol Lett       Date:  2016-02-09       Impact factor: 2.967

10.  Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer.

Authors:  Jong-Young Lee; Seok Joong Yun; Pildu Jeong; Xuan-Mei Piao; Ye-Hwan Kim; Jihye Kim; Sathiyamoorthy Subramaniyam; Young Joon Byun; Ho Won Kang; Sung Phil Seo; Jayoung Kim; Jung Min Kim; Eun Sang Yoo; Isaac Y Kim; Sung-Kwon Moon; Yung Hyun Choi; Wun-Jae Kim
Journal:  Oncotarget       Date:  2018-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.